AstraZeneca Pharma India updates on exploring contract manufacturer
The company will now explore a buyer for its manufacturing site and exit in due course
The company will now explore a buyer for its manufacturing site and exit in due course
Approval based on CAPItello-291 results which showed this combination reduced the risk of disease progression or death by 50% vs. Faslodex alone in a biomarker-altered population
Austin assumes role from Glenn F. Tilton, who will continue to serve as an independent director
Second FDA approval for KRAZATI - reinforcing its potential across tumor types
Dabigatran Etexilate Capsules are indicated for reduction of risk of stroke and systemic embolism in non-valvular atrial fibrillation in adult patients
Augtyro is the only FDA-approved treatment option for NTRK-positive tumors studied in both TKI-naïve and TKI-pretreated patients across solid tumors
Jubilant's Radiopharma Business to expand positron emission tomography radiopharmacy network
Higher efficacy was observed in mRNA-1283 compared to Spikevax in adults 18 years of age and older
Azilsartan Medoxomil and Chlorthalidone Tablets had annual sales of US$ 77.9 mn in the United States (IQVIA MAT March 24).
Subscribe To Our Newsletter & Stay Updated